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Abstract
This study sets up a compound option approach for evaluating phar-
maceutical R&D investment projects in the presence of technical and eco-
nomic uncertainties. Technical uncertainty is modeled as a Poisson jump
that allows for failure and thus abandonment of the drug development.
Economic uncertainty is modeled as a standard di¤usion process which
incorporates both up-and downward shocks. Practical application of this
method is emphasized through a case analysis. We show that both uncer-
tainties have a positive impact on the R&D option value. Moreover, from
the sensitivity analysis, we nd that the sensitivity of the option with
respect to economic uncertainty and market introduction cost decreases
when technical uncertainty increases.
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1 Introduction
New drug development is a lengthy process, which is scrutinized at every stage
of development by the United States Food and Drug Administration (FDA) in
the USA and respective regulatory agencies in various countries. Not every com-
pound that is tested in laboratory is eventually marketed. Only one of every
10,000 potential medicines investigated by Americas research-based pharma-
ceutical companies makes it through the research and development pipeline and
is approved for patient use by the FDA. Winning approval, on average, takes
15 years of research and development and costs over $800 Million dollars1 .
Potential new medicines pass through several crucial stages on their way
from research laboratories to the pharmacy shelf. The starting point is an
extensive discovery phase devoted to performing directed and highly focused
research to identify and validate a therapeutic target. The development phase
is focused on identifying a compound that selectively modulates the function
of the target that was identied in the discovery phase. Pre-clinical studies
involve tests on mammals (animal-model) and human cells. The main goals of
pre-clinical studies are to understand adverse e¤ects of the drug during clinical
trials. If these tests are successful, a pharmaceutical rm applies at the public
health agency (FDA or EMEA-European Medicines Agency) for the approval to
starting testing in humans. The clinical testing process is known as Investigation
New Drug (IND) application and includes three di¤erent phases: (a) Phase 1,
(b) Phase 2, (c) Phase 3. Phase 1 involves tests on 20-100 healthy volunteers
to determine safety and dosage. Phase 2 involves tests on 100300 patient
volunteers to establish the e¤ectiveness of the drug and look for side e¤ects.
Phase 3 involves tests on 10005000 patient volunteers to verify e¤ectiveness
of the drug and monitor adverse reactions from long-term use. Once all three
phases of the clinical trials are complete, a company analyzes all of the data. If
the ndings demonstrate that the potential medicine is both safe and e¤ective,
the company les a New Drug Application (NDA) with the agency for marketing
approval. If the medicine is approved, or "cleared for marketing," it becomes
available for patients.
The drug development process is risky in that most compounds that undergo
clinical trials are abandoned without obtaining marketing approval. Reasons for
research abandonment are generally grouped into 3 major categories2 : safety,
e.g. human toxicity or animal toxicity; e¢ cacy, e.g. activity too weak or lack
of e¢ cacy; economics, e.g. commercial market too limited or insu¢ cient return
on investment. The success rate at which compounds move from phase to phase
of drug development is also sometimes called attrition rate. Team of chemists,
in general, sends an average of 10,000 new chemical entities to the pre-clinical
development unit for testing. Only 250 of these will pass the criteria of activity
and lack of toxic side e¤ects which are set by the study team. Of the 250
for which IND applications are submitted to FDA, about 30 will successfully
1Source: Pharmaceutical Research and Manufacturers of America (PhRMA):
http://www.phrma.org/innovation/.
2See DiMasi (2001) for further details.
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complete Phase 1 trials and go on to Phase 2; about 5 of the original 250 will
complete Phase 2 and go to Phase 3; and 3 to 30 of the original 250 will succeed
after Phase 3. Sometimes compounds are to be dropped o¤ during regulatory
approval process3 . A feature that is fairly unique to the pharmaceutical rms
investment project is the fact that, in general, the complete value of a project
is lost upon the failure of a laboratory test. Accordingly, the failure of one
of the stages results in overall project termination. Figure 1 shows a typical
development path of a new medicine.
FIGURE 1: typical development path of a new medicine
In this paper, we tackle the problem of valuing pharmaceutical rms R&D
investment projects that are subject to technological uncertainty, i.e. in which
the drug development activities carry a risk of failure, and where an activitys
failure results in the projects overall failure. The main goal is to model the tech-
nical risk of failure as a Poisson-type jump process, in which if a drug candidate
fails (e.g. is revealed not to have the desired properties or because of harmful
side e¤ects), during the drug development process, the project is abandoned,
as its value falls to zero. On the other hand, if the drug candidate success-
fully passes laboratory and clinical tests, the company can proceed with market
launch. Uncertainty related to the success/failure of R&D activities is the major
concern for R&D managers in the pharmaceutical industry. If the R&D activity
is unsuccessful, indeed, there is no product to commercialize. In addition to
technical risks, the potential drug candidates are also exposed to a signicant
3Source: http://www.innovation.org/index.cfm/nonav/Inside_R_&_D#link8.
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amount of economic uncertainty, which is a function of factors exogenous to the
project, such as general market conditions. This source of uncertainty is mod-
eled as a standard di¤usion process which incorporates both up-and downward
shocks. It often appears di¢ cult in valuing investment projects to estimate
economic uncertainty of the project value, while technical risk seems easier to
estimate. Furthermore, data for market introduction costs are usually not read-
ily available. We show that, in the presence of technical risk, both parameters
in our model have a lower impact on the value of the investment project as
compared to the model that does not account for technical risk.
The paper is structured as follows. Section 2 provides an overview of the
related economic literature. Section 3 describes the setup of the model and
derives a closed-form expression for valuing compound R&D options when the
underlying process follows a Poisson jump-di¤usion, with the risk of complete
project failure. Section 4 provides an application of this model through a case
analysis. In the simulations, we analyze a pharmaceutical R&D project with
the risk of failure in all R&D stages and the same absent the risk of failure to
determine the value of a compound R&D option. Detailed sensitivity analyses
are shown as to deepen our understanding of the determinants of the compound
R&D option value. Finally, section 5 concludes the paper.
2 Literature review
Risk and exibility involved in research and development activities make valua-
tion of pharmaceutical rms investment projects a non-trivial task. Traditional
valuation techniques such as those using a standard discounted cash ows (DCF)
analysis are of limited value in this context. Because of a high level of uncer-
tainty, the real options valuation (ROV) is a signicant alternative for valuing
pharmaceutical R&D investments, but additional elements are required for a
reasonable value to be obtained. In fact, the pharmaceutical rms investment
project may be interpreted as an option to expand to other (follow-on) projects.
In particular, provided that the immediate investment project(i.e. drug dis-
covery) succeeds, it may be opportune to start a second project(pre-clinical
testing). Similarly, if this second project is successful, it may be convenient
to enter a third project (Phase 1 clinical trials). Moreover, if this project
is started, it may be opportune to enter a fourth project(Phase 2) and so on
until the ultimate project(market launch). From a corporate nance stand-
point, this is an obvious exibility. Since management has the right to run the
project actively, this exibility has value. From a ROV standpoint, this ex-
ibility has a form of a compound call option. Essentially, compound options
are combinations of options, where an exercise of an option opens up another
option. Compound options have been extensively used in the nance litera-
ture to evaluate sequential investment opportunities. Geske (1979) shows that
risky securities with sequential payouts can be valued as compound options.
Carr (1988) analyzes sequential compound options, of the form of options to
acquire subsequent options to exchange an asset for another asset. Lee and
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Paxson (2001) have applied Carrs compound exchange option formula to R&D
investments valuation. In the real options theory, applications of compound op-
tions are commonly found in a number of industrial projects, but are especially
relevant for pharmaceuticals where the project gives the real option to further
research, or to start the implementation of the results. Consequently, compound
option pricing has been proposed for valuing pharmaceutical R&D in the cap-
ital budgeting literature4 . Shockley et al. (2003) adopt a multistage binomial
option pricing model to compute the option value of an early-stage biotechnol-
ogy investment. Cassimon et al., (2004) derive a closed-form expression for a
N-nested compound option and have successfully applied it to assess the value
of a NDA. These papers do not specify a clear distinction between technical
and economic uncertainties5 ; they assume that uncertainty is one-dimensional
by modeling the underlying value as a geometric Brownian process. An ex-
ception is Copeland and Antikarov (2001) who model two types of compound
R&D options using binomial lattice methods. First, they model a two-phase
R&D programme that depends on a single source of uncertainty. Second, they
consider a rainbow type compound option in which the value of the underlying
project is driven by two sources of uncertainty. Most importantly, they show
how to separate technical and economic uncertainties and to model their e¤ects
on the project value using the quadrinomial approach (cf. chapters 10-11).
The contribution of this paper is in specifying a clear distinction between
technical and economic uncertainties and in showing how they act together.
Di¤erently from Copeland and Antikarov (2001), we set up a compound real
option model where information arrives both continuously and discontinuously
over time. We stress that the standard compound option formula provides a
naïve instrument for evaluating pharmaceutical R&D investment projects, since
it does not allow one to take technological uncertainty (the success or failure of
the project) into account. In our model there is a positive probability that the
project fails due to the arrival of a technical failure. This probability of failure
follows a Poisson distribution per unit of time. Combining a Poisson jump
and a di¤usion process, we are able to study a compound R&D option that
allows for the possibility of abandoning the project at each development phase.
The proposed Poisson jump-di¤usion compound option model is applied in a
practical business setting, through a case study application. Since it shows how
to apply a compound option method to value a pharmaceutical R&D investment
project it has also a straightforward practical use.
4R&D investments are modeled as simple European compound call options in this litera-
ture.
5 In the real options theory, Pindyck (1993) is one of the rst to make a distinction between
the e¤ect of technical and market uncertainty on real option value. Technical uncertainty in
his paper relates to the cost to complete an investment project and can only be resolved by
the rm by undertaking the investment project. Market uncertainty a¤ects input costs and
is external to what the rm does. He shows that both uncertainties have a positive impact
on the option value. Our results for technical and economic uncertainties coincide with those
obtained by Pindyck (1993), even though our measure of technical uncertainty is technical
failure. Our measure seems more adequate as there is low uncertainty about the cost of
completion, but a high uncertainty about the chance that the product is e¤ective.
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3 ACompound option model for evaluating phar-
maceutical R&D investment projects
Our aim in this section is to set up a compound real option model for evaluating
the pharmaceutical rms investment project in the presence of technical risk
of failure. For the purposes of clarity and illustration, we depart from a model
that is as simple as possible, i.e. a call on a call option with two strike prices
and two maturity dates. The basic intuition underlying this model is illustrated
as follows. At time zero, beginning of the discovery phase, the pharmaceuti-
cal company has the option of developing and manufacturing a new drug by
investing an amount I2 (strike price of the compound option) at exercise date
T2. If this project is successful, the company has another option of proceeding
with product commercialization by investing an amount I1 (strike price of the
option) at exercise date T1; T2 < T16 . Figure 2 shows the compound R&D
option structure.
FIGURE 2: compound R&D option structure
6The value of a compound option, without technical risk of failure, has been derived by
Geske (1979):
f2 (V; 0) = V0@2 (a2; a1; )  e rT1I1@2 (b2; b1; )  e rT2I2@1 (b2) ;
where f2 (V; 0) is the value of the compound option; V0 is the current value of the under-
lying asset; I1 is the exercise price of the underlying option; I2 is the exercise price of
the compound option; T1 is the exercise date of the option; T2 is the exercise date of the
compound option; r is the risk-free interest rate; @2 (x; y; ) is the standard bivariate nor-
mal distribution function evaluated at x and y with correlation coe¢ cient of  =
p
T2/T1;
a1 =

ln

V0
I1

+
 
r + 1
2
2

T1
. 

p
T1

; a2 =

ln

V0
v2

+
 
r + 1
2
2

T2
. 

p
T2

; b1 =
a1   
p
T1; b2 = a2   
p
T2;  is the volatility of the underlying asset and v2 is the
critical value of the asset such as the underlying option is at the money at time T2:
The expression V0@2 (a2; a1; ) can be interpreted as the present value of receiving the asset
at expiration of the option, contingent upon both the compound option and the underlying
option nishing in the money; the expression e rT1I1@2 (b2; b1; ) can be interpreted as the
present value of paying the exercise price I1 in that event, and nally, e rT2I2@1 (b2) can be
interpreted as the present value of paying the exercise price I2 contingent upon the compound
option nishing in the money. See Lajeri-Chaherli (2002) for further details.
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The underlying state variable in our model is the present value of all future cash
ows (hereafter referred to as project value) received at time t, which is assumed
to follow a mixed jump-di¤usion process. Numerous previous studies have set
up models of R&D investments valuation using a Poisson-type jump process7 ,
in which the value of the underlying project may undergo nitely many jumps
in every time interval and the size of the jumps is stochastic. Examples that are
well-modeled as Poisson processes include the arrivals of competitors, litigations
of patent rights, innovations in technology and important breakthroughs. For
the pharmaceutical rms R&D investment project, we assume that the arrival
of important information is modeled as a Poisson jump process, with only one
jump in every time interval. In our model, the jump represents the possibility of
a complete ruin of the project underlying a drug development process. Therefore
the size of the jump is assumed to be constant and non-stochastic.
The specication of the project value dynamics in the presence of technical
risk of failure is given in the following section. For the sake of clarity, we discuss
the construction of the simplied jump-di¤usion model starting from a more
general jump-di¤usion model.
3.1 Project value dynamics in the presence of technical
risk of failure
The project value is uncertain during the di¤erent stages. Denoting by Vt the
time t 2 [0; T1] valuation of the project, we assume that Vt follows a log-normal
jump-di¤usion process (Merton, 1976). The underlying project value as given by
the jump-di¤usion model has two sources of uncertainty: the di¤usion risk dzt
(typical of ordinary businesses) which incorporates both positive and negative
random uctuations, and the term dqt which describes the arrivals of major
shocks that imply an abrupt increase/reduction in V . On average, there are t
jumps in the time interval [0; t], the average relative jump size is E [Y   1] and
the number of jumps is independent of the size of jumps and also independent
of the remaining uncertainty in the model.
For the pharmaceutical rms investment project, it seems more appropriate
to employ a simplied version of the jump-di¤usion model, in which Y is non-
stochastic and there is either zero or one jump in the project value in a time
interval of length t. In more specic terms, we consider the jump-di¤usion
model:
Vt = V0e
(  122)t+ztt; (1)
where  is the expected rate of return on the project,  is the standard deviation
of the project, zt is a standard Brownian process, and V0 is the current value of
the underlying project. In the above equation, t is the variable with technolog-
ical uncertainty which describes the likelihood of success of the pharmaceutical
R&D project. In more specic terms, this is the exponential of the product
7See, for example, Pennings and Lint (1997), Martzoukos and Trigeorgis (2002) and Wu
and Yen (2007) :
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of a Poisson random variable nt (independent of zt) with parameter  (> 0),
which describes the likelihood of occurrence of the jump, and a deterministic
component ln (Y ), which describes the jump amplitude. In particular:
t = e
nt ln(Y ):
In our study, we assume that there is only possible jump (nt = 0 or nt = 1)8
and, if there is a jump, the project becomes worthless. Hence,
t =

1 with probability e t fif a technical failure does not occurg
0 with probability 1  e t fif a technical failure occursg
and its expected value is E [t] = e
 t:
We will assume that the rm is risk neutral, so that replacing the expected
rate of return  in (1) by  = r+ , where r  0 denotes the risk-free interest
rate and  is the market price of di¤usion risk, the terminal value of the project
Vt can be rewritten as:
Vt = V0e
(r  122)t+zt t:
z = z+t is a new Brownian motion process under the risk-neutral probability
measure, z and nt are as above independent of each other. Note that in such a
context the jump is not correlated with the general movements of the economy.
It represents idiosyncratic risk that can be diversied away and have a zero
market price of risk in equilibrium9 .
Risk-neutrality, meaning that the weighted average of the zero-jump and one-
jump current expected value of the project equals the future value of the project,
is maintained by dividing the current value of the project by the expected value
of the jump. Hence,
Vt =
V0
e t
e(r 
1
2
2)t+zt t;
which implies that the deterministic drift component of the process (1) is re-
placed by the risk-neutral drift
 
r +   122

, where  is the compensation for
the technical jump risk in the time interval [0; t]. Because rational investors
would not be willing to invest in assets yielding inadequate returns, they have
to be compensate for additional jump risk10 .
8From the properties of Poisson processes, we have that Pr (nt = i) = e t (t)
i
i!
, i = 0; 1; :::
is the probability that there are exactly i occurrences in the time interval [0; t]. For a drug
development process, only the rst jump in the time interval [0; t] is relevant, therefore i = 0:
As a result, Pr (nt = 0) = e t; is the probability that technical failure will not have occurred
at time t: Hereafter, this is referred to as the success probability of the pharmaceutical R&D
project.
9This means that the jump component of V is unchanged under the risk-neutral probability
measure.
10As shown by Merton (1976) the option price is an increasing function of , and therefore
an option on a stock that has a positive probability of complete ruin is more valuable than an
option on a stock that does not.
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Hereafter, R&D investment options are valued as if the project value at any
future time t is conditioned on two possible scenarios, a failure occurs and does
not occur11 . In more specic terms, let us denote by Vtj (nt = 1) ; the terminal
value of the project, conditioned on knowing that a technical failure occurs
during the interval [0; t]. This can be written as:
Vtj (nt = 1) = V0e(r+  12
2)t+zt t
 (nt = 1) (2)
= 0;
and its expected value is:
E [Vtj (nt = 1)] = 0:
Moreover, let us denote by Vtj (nt = 0) ; the terminal value of the project, con-
ditioned on knowing that a technical failure does not occur during the interval
[0; t]. This value is:
Vtj (nt = 0) = V0e(r+  12
2)t+zt t
 (nt = 0) (3)
= V0e
(r+  122)t+zt :
The expected value of Vtj (nt = 0), is12 :
E [Vtj (nt = 0)] = V0e(r+)t:
Note that we assume for simplicity that information about the success or failure
of the project is revealed at the end of each stage. Consequently, each investment
option will only be exercised if all the activities scheduled to nish the R&D
project have a positive outcome.
3.2 Valuing a single stage option
Consider the valuation problem of a R&D-based pharmaceutical rm who, at
time zero, has an option to launch a product on the market. Let T1 be the time
of the market launch of the product, when, upon bearing the commercialization
cost I1, the rm pockets the project value VT1 . The project payo¤ at time T1
is max fVT1   I1; 0g and let F1 (V; t) denote the value at time t of this simple
investment opportunity. Then, if the value of V at time T1, is greater than I1,
11The trade-o¤ for using a more realistic jump-di¤usion process is that the terminal value
of the project Vt is no longer log-normal because t is not log-normal. Within this framework
the probability density function of V cannot be explicitly written. This makes valuation of
compound R&D options a non-trivial task. We address this problem by conditioning on the
random event occurrence, and work with the conditional variable thereafter.
12Since zt  @
 
0;
p
t

, we have that      1
2
2t+ zt
  @    1
2
2t; 
p
t

and therefore
e is lognormally distributed with E

e 

= e( 
1
2
2t+ 1
2
2t) = 1:
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the product will be marketed, i.e. the option will be exercised, while for values
less than I1 it will be abandoned.
The time zero value of this investment opportunity is the expected present
value of these cash ows and is given by:
F1 (V; 0) = e
 rT1E0 [max fVT1   I1; 0g] :
Valuing the investment opportunity F1 (V; 0) from a jump-to-ruin process is
straightforward. Let us dene n as the number of jumps that occur in a time
interval of length T1. The occurrence of a jump decreases the project value to
zero and the random variable n takes the values of zero with probability e T1
or one with probability 1   e T1 . By conditioning on the two scenarios, we
can express F1 (V; 0) as a weighted sum of the call option prices given that a
technical failure occurs and does not occur:
F1 (V; 0) = e
 rT1 Pr (n = 1)E0 [max fVT1   I1; 0gj n = 1] + (4)
+e rT1 Pr (n = 0)E0 [max fVT1   I1; 0gj n = 0] :
The value of the rst expectation in (4) can be found easily. By condition-
ing on the occurrence of a technical failure, the terminal value of the project
at time T1 can be written as VT1 j (n = 1) = 0. This can be obtained by a
straightforward application of formula (2). It follows that the expected nal
value, E0 [max fVT1   I1; 0gj n = 1] ; of the option is worthless since its payo¤
becomes zero.
Now, let us concentrate on the second term in (4). The terminal value of
the project, VT1 ; conditioned on the absence of a technical failure, is
13 :
VT1 j (n = 0) = V0e(r+ 
1
2
2)T1+zT1 :
The problem of computing the value of a single call option with the jump-to-
zero risk reduces to the standard problem of computing the value of a single call
option with an increased discount rate:
F1 (V; 0) = e
 rT1e T1E0
h
max
n
V0e
(r+  122)T1+
p
T1u   I1; 0
oi
:
Hence,
F1 (V; 0) = e
 T1  V0eT1@1 (h1)  I1e rT1@1 (l1) ; (5)
where @1 () is cumulative standard normal distribution, and the terms h1 and
l1 are given by:
h1 =
ln

V0
I1

+
 
r + + 12
2

T1

p
T1
;
13This can be obtained by a straightforward application of formula (3).
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l1 = h1   
p
T1:
According to (5) the formula is the same as the Black-Scholes (1973) call option
formula, given that the technical failure does not occur during the lifetime of
the option, weighted by the probability of no technical failure. The expression
e T1
 
V0e
T1@1 (h1)

can be interpreted as the present value of receiving the
future cash ows contingent on the success of the project and the exercise of the
option, and the expression I1e (r+)T1@1 (l1) can be interpreted as the present
value of paying the strike price I1 in that event.
3.3 Valuing a compound R&D option
Consider now the valuation of a compound R&D option which, at time T2, gives
the rm the right to pay I2 to buy another option, the underlying option, that
has an exercise price I1 and exercise date T1. At time T1, the underlying option
gives the right to launch the product. The payo¤ of the compound option at
time T2 is
F2 (V; T2) = max fF1 (VT2 ; 1)  I2; 0g ;
where F1 (VT2 ; 1) stands for the value at time T2 of a simple call option with
exercise price I1 and expire date T1 = T2+1: Therefore, if at time T2 the value
of the option is greater than the strike price I2 the compound option will be
exercised, while for values less than I1 it will be abandoned.
The time zero value of the compound option is the expected present value
of these cash ows and is given by:
F2 (V; 0) = e
 rT2E0 [max fF1 (VT2 ; 1)  I2; 0g] :
The evaluation of this option requires conditioning on two possible scenarios, a
failure occurs and does not occur, in the intervals [0; T2] and (T2; T1]. In more
specic terms, let us dene n2 and n1 as the number of jumps that occur in the
intervals [0; T2] and (T2; T1], respectively. Recall that 1 = T1   T2. Thus the
random variables n2 and n1 are independent Poisson variates with respective
probabilities e T2 and e 1 if the jump does not occur and probabilities 1 
e T2 and 1  e 1 if the jump occurs.
We know that F1 (VT2 ; 1) is given by straightforward application of formula
(5). Thus:
F1 (VT2 ; 1) = e
 1  VT2e1@1 (h1 (VT2 ; 1))  I1e r1@1 (l1 (VT2 ; 1)) ;
where:
h1 (VT2 ; 1) =
ln

VT2
I1

+
 
r + + 12
2

1

p
1
;
l1 (VT2 ; 1) = h1 (VT2 ; 1)  
p
1:
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Consequently, the value at time zero of the compound option is:
F2 (V; 0) = e
 rT2 Pr (n2 = 1)E0 [max fF1 (VT2 ; 1)  I2; 0gjn2 = 1] + (6)
= e rT2 Pr (n2 = 0)E0 [max fF1 (VT2 ; 1)  I2; 0gjn2 = 0] ;
We know that if a technical failure occurs in the interval [0; T2] ; the conditional
value of the project at time T2, is:
VT2 j (n2 = 1) = 0;
and consequently the expected nal value, E0 [max fF1 (VT2 ; 1)  I2; 0gjn2 = 1],
of the compound option is worthless since its payo¤ becomes zero.
On the other hand:
VT2 j (n2 = 0) = V0e(r+ 
1
2
2)T2+zT2 ;
is the terminal value of the project at time T2, conditional on knowing that
a technical failure does not occur during the interval [0; T2]. Therefore, the
valuation problem boils down to:
F2 (V; 0) = e
 rT2e T2E0 [max fF1 (VT2 ; 1)  I2; 0gjn2 = 0] ;
which can be written as:
F2 (V; 0) = e
 rT2e T2
+1R
u2

e 1

v2(u)e
1@1

h^1

  I1e r1@1

l^1

  I2

n (u) du;
where n (:) is the normal density function, h^1 = h1 (v2(u); 1), l^1 = l1 (v2(u); 1),
the function v2 : R  ! R is given by:
v2(u) = V0e
(r+  122)T2+
p
T2u;
and, nally, the constant u2 is dened implicitly by the equation:
u2 = inf fu 2 R j F1 (v2(u); 1)  I2g :
The value at time zero of the compound option, is:
F2 (V; 0) = e
 T1  V0eT1@2 (h2; h1; )  I1e rT1@2 (l2; l1; )+
 e (r+)T2I2@1 (l2) ;
(7)
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where:
h1 =
ln

V0
I1

+
 
r + + 12
2

T1

p
T1
; l1 = h1   
p
T1;
h2 =
ln

V0
V 2

+
 
r + + 12
2

T2

p
T2
; l2 = h2   
p
T2;
Factor @2 (x; y; ) is the standard bivariate normal distribution function eval-
uated at x and y with correlation coe¢ cient of  =
p
T2/T1, and V 2 is the
critical value of the project such that the underlying option is at the money at
time T2; i.e.
v2(u) = V

2 ;
where V 2 solves the equation:
e 1
 
V 2 e
1@1 (h1 (V 2 ; 1))  I1e r1@1 (l1 (V 2 ; 1))

= I2:
According to (7) the pricing formula is the same as the Geskes (1979) com-
pound option formula, given that the technical failure does not occur during
the intervals [0; T2] and (T2; T1], weighted by the probabilities of no-technical
failure. The expression e T1
 
V0e
T1@2 (h2; h1; )

can be interpreted as the
present value of receiving the future cash ows contingent on the success of
the discovery and development phases and the exercise of both the compound
and the underlying options. The expression e (r+)T1I1@2 (l2; l1; ) can be in-
terpreted as the present value of paying the strike price I1 in that event and
nally, the expression e (r+)T2I2@1 (l2) can be interpreted as the present value
of paying the strike price I2 contingent on the success of the discovery phase
and the exercise of the compound option.
4 Case study application
To test our model in a practical business setting, it is applied to a case analysis.
We provide a valuation of an R&D project using as much as possible data
provided by one of the largest oncology-focused R&D companies in Europe14 .
The company is developing a pipeline of products aimed at a better treatment
for cancer. R&D activity is therefore devoted to the understanding of cancer
mechanisms instrumental in the denition of novel approaches to the treatment
of this disease. Because of the high condentiality of many issues, all key-dates
and nancial values presented in this document are modied.
According to the companys R&D programme, the drug development project
moves from one stage to another according to a pre-dened stage-gate process
14For condentiality reasons, we cannot disclose the name of the company, nor provide more
detailed information of the invention.
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as described above. Milestone projects for the drug under consideration can be
easily summarized as follows. The drug R&D project started in 2003 with the
discovery of a new molecule. Pre-clinical testing started in 2007 and took one
year to complete. At present time (year 2009), the candidate drug has success-
fully completed the rst phase of clinical tests on humans, and will shortly be
introduced into Phase 3, during which its e¤ect on a large number of oncological
patients will be tested. The company expects to enter into Phase 3 in 2011. It
often takes an average of 3 years to complete Phase 3, depending on the length
of the study, and the number of volunteers. If the clinical testing is completed
with a successful outcome, documentation detailing clinical results is submitted
to the EMEA for approval. The company expects to le a NDA with EMEA for
marketing approval in 201415 . As noted above, a drug product must be found to
be e¤ective and safe before it may be approved for general marketing. Provided
that the drug is approved by the agency, the expected year of market launch is
2015.
4.1 Compound R&D option structure
In order to complete the drug development project, and to launch the product
into the market, the company still faces two investment decisions:
(1) decision to enter into Phase 3 (year of exercise 2011);
(2) decision to launch the drug (year of exercise 2015).
The two discrete investment decisions can be considered as investment op-
tions whose values are priced by using technique of compound options. Ac-
cordingly, we perform a compound option valuation of the drug development
project, as of January 2010, given what is known at the end of 2009. To trans-
fer our theoretical model to the case study application, some specications to
the model are necessary.
The call option F1 can be exercised at the beginning of 2015 when the
company will decide to commercialize the drug or to abandon. The lifetime of
the option is 5 years (exercise date) and its nal payo¤ is equal to the di¤erence
between the 2015 value of the project and the present value of the phased
investment (the capital expenditure to be made to launch the drug into the
market) at year 2015. The value of the project is the present value of all future
cash ows, received at the beginning of year 2015. This value is conditional
on knowing that a technical failure does not occur during years 2010-2011 and
2011-2015. Provided that the project is successful, the company should exercise
the call option if the value of the project is greater than the investment at year
2015. If on the other hand the project value is less that the investment, the
company should abandon the option.
The compound option F2 can be exercised at the beginning of 2011 when
the company will decide to enter into Phase 3 or to abandon. The lifetime of the
15For simplicitys sake, we assume that all decisions regarding the completion of the R&D
project will be taken at the beginning of each year.
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compound option is 1 year and its nal payo¤ is equal to the di¤erence between
the 2011 value of the underlying option and the present value of the phased
investment (the capital expenditure to be made to develop and manufacture the
drug) at year 2011. The 2011 value of the underlying option is conditional on
knowing that a technical failure does not occur during the life of the compound
option. Provided that the project is successful, the company should exercise
the compound option if the value of the underlying option is greater than the
investment at year 2011. If, on the other hand, the value of the underlying
option is less that the investment the company should abandon the compound
option.
The problem of valuing the drug development project is thus reduced to the
problem of pricing the compound option F2:
4.2 Input parameters
The variables considered when valuing the pharmaceutical R&D investment
project by means of the formula (7) are illustrated in Table 1.
TABLE 1: description of the variables of the compound option
model
RO variable Empirical equiva-
lent
Value
Current value of the
underlying asset (V0)
Project value:
present value of
all future cash ows
(PV2010)
V0 = e67 Million
Strike price of the un-
derlying option (I1)
Present value of the
phased investment at
year 2015
I1 = e27 Million
Strike price of the
compound option
(I2)
Present value of the
phased investment at
year 2011
I2 = e19 Million
Exercise date of the
option (T1)
Lifetime of the option
to launch the drug
T1 = 5 Years
Exercise date of the
compound option
(T2)
Lifetime of the option
to go into Phase 3
T2 = 1 Year
Volatility of the un-
derlying asset of the
option ()
Volatility of the
project value
 ranges from 23% to
57%
15
Risk-free interest rate
(r)
Annual interest rate
of T-bonds with a
maturity date of 5
Years
r = 2:4%
Annual arrival inten-
sity ()
Annual arrival inten-
sity
 = 7:6%
1. Current value of the underlying asset (V0). This is the 2010 present
value of all future cash ows from the project, excluding the phased investments
(i.e. capital expenditures to be made to develop, manufacture and launch the
drug into the market). The reason is that they will be subtracted as exercise
prices in the compound option model. Finally, technical uncertainty will be
directly accounted in the compound option computation through the multipli-
cation of the underlying value and the exercise prices by their corresponding
probabilities of success. The 2010 the present value of the underlying asset can
then be computed performing a standard DCF analysis16 . We obtain that V0 =
e67 Million.
2. Strike prices of the underlying and compound options (I1 and
I2). During the analysis of the compound option structure we identied that the
present value of the phased investments of the drug development and marketing
process represent the option exercise prices. Their values are presented in Table
1.
3. Exercise dates of the underlying and compound options (T1
and T2). During the previous analysis we identied that the exercise date
of the call option is equal to the lifetime of the option to launch the drug
(i.e. T1 = 5 Years) ; and that the exercise date of the compound option is equal
to the lifetime of the option to enter into Phase 3 (i.e. T2 = 1 Year) :
4. Volatility of the underlying asset of the option (): With any
option pricing model the key element to determine is volatility. When used for
valuing nancial options, is usually measured by the volatility of the underly-
ing stock or a group of similar stocks. This is much more di¢ cult with real
projects17 . One could look to the revenue or cash ow volatility (if such data
are available) or use the volatility of similar projects. Some18 have suggested
using the volatility in stock prices of other rms in the same business. For our
analysis, we use the stock price volatility of a NASDAQ listed biotech rm that
develops a similar kind of product as a proxy for the volatility of the project
value. This value can be taken from the historical stock price volatility of AM-
GEN Inc.19 The range for the volatility of the project value is set at 23% to
57%.
16For condentiality reasons, nancial data and valuation results that can be disclosed for
this project are limited.
17The problem with real options is that the underlying project is non-traded asset, which
makes nding an estimate for the volatility di¢ cult.
18See, for example, Nichols (1994).
19Source: http://dynamic.nasdaq.com/dynamic/nasdaqbiotech_activity.stm.
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5. Risk-free interest rate (r): The value of the risk-free rate is the annual
interest rate of Treasury Bonds with the same maturity date as the exercise
date of the underlying option. This value is taken from Bloomberg20 (Date:
November 10, 09) and it is about 2:4% (e.g. we use a 5-Year coupon rate of
U.S. Treasury Bonds).
6. Annual arrival intensity () : This is the annual arrival intensity of
important information. The annual arrival intensity is determined based on
the rms estimations of the probabilities of success of the project in the R&D
stages. These probabilities of success are determined based on the average rates
in the biopharmaceutical industry and adjusted by clinical experts to better
reect specic project characteristics. Table 2 presents the milestone projects
and the associated probabilities of success.
TABLE 2: milestone projects and associated probability of success
Phase Start date Duration
(Years)
Probability
of success
Phase 2 in progress 1 80%
Phase 3 2011 3 90%
Approval 2014 1 95%
Launch 2015
Hence, with probability of 80% the project will show positive results in Phase
2, with probability of 90% it will show signicant e¤ectiveness in treating pa-
tients during Phase 3, and there is 95% probability that it can gain EMEA
approval. This makes up 68:4% of cumulative probability that the project will
be marketed. The annual arrival intensity can then be computed as:
e T1 = e 5 = 0:684
Hence,
 = 0:076:
4.3 Numerical results
In this section we provide some numerical results on compound R&D options. In
order to implement the analytical solution and to study its sensitivity analysis
with respect to important value drivers we use Mathematica Programming.
Assuming an initial project value of e67Million, investment costs of e27Million
and e19Million, maturities of 5 Years and 1 Year, a volatility of 23%, a risk-free
interest rate of 2:4% and a probability of failure of 7:6%, we obtain:
F2 (67) = e
 0:0765  67e0:0765  0:997856  e 0:024527  0:991902+
 e (0:024+0:076)119  0:998265 = e 33:4 Million.
20Source: http://www.bloomberg.com/markets/rates/index.html.
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Now, instead assume no technical uncertainty (i.e.  = 0):
f2 (67) = 67  0:985953  27e 0:0245  0:955848+
 19e 0:0241  0:995234 = e 24:7 Million.
Numerical results show that technical uncertainty increases the value of an R&D
investment opportunity, i.e. an R&D project that has a positive probability of
failure is more valuable than an R&D project that does not.
The table below provides the sensitivity analyses of the compound R&D
option value for di¤erent values of V0,  and .
TABLE 3: sensitivity analyses of the compound R&D option value for dif-
ferent values of V ,  and  (values in Million of e)
 No-Technical
Uncertainty
 = 0:076  = 0:1
 23% 48% 57% 23% 48% 57% 23% 48% 57%
V0
67 24.7 28.9 31.1 33.4 35.2 36.6 35.7 37 38.1
75 32.6 36.1 38.2 41.4 42.8 44 43.7 44.7 45.7
90 47.5 50.1 52.0 56.4 57.4 58.4 58.7 59.4 60.2
100 57.5 59.6 61.4 66.4 67.2 68.1 68.7 69.2 70
The e¤ect of these elements on the resulting compound R&D option value
is as follows:
(1) an increase in the value of the underlying project will cause the compound
R&D option value to increase;
(2) an increase in the volatility of the value of the underlying project will
cause the compound R&D option value to increase;
(3) an increase in the annual arrival intensity will cause the compound R&D
option value to increase.
Figure 3 shows the relation between the compound R&D option values and
the project value. The e¤ect of technical uncertainty is investigated through two
di¤erent curves. The dashed curve illustrates the sensitivity of the compound
R&D option value F2 with the project value in the presence of technical uncer-
tainty, while the solid curve illustrates the sensitivity of the compound R&D
option value f2 with the project value absent technical uncertainty. As before
we assume: I1 = 27; I2 = 19;  = 23%; T1 = 5; T2 = 1, r = 2:4%,  = 7:6% and
V0 ranges from 20 to 100: The gap between the two curves shows the increased
value by incorporating technical uncertainty into a model of compound R&D
option valuation. For low values of V , the two curves are close to each other,
as the option is out of the money regardless of the presence of technical failure.
Figure 4 shows the relation between the compound R&D option values and
the volatility of the project value. The dashed curves illustrate the sensitivity of
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the compound R&D option value F2 with the project volatility in the presence
of technical uncertainty, while the solid curve illustrates the sensitivity of the
compound R&D option value f2 with the project value absent technical uncer-
tainty. The following parameter values are used: V0 = 67; I1 = 27; I2 = 19;
T1 = 5; T2 = 1, r = 2:4%;  = 7:6% (short dashes) and 10% (long dashes)
and nally  ranges from 20% to 100%: As gure 4 clearly shows, increasing
the market volatility increases the option value. We can, moreover, make some
remarks about the Vegaof the option, dened as the sensitivity of the option
with respect to the volatility of underlying value. The Figure shows that the
option Vegadecreases when technical uncertainty increases. As an important
consequence, this means that errors in the estimate of economic uncertainty are
less important when accurate estimates of signicant technical risk of failure
exist.
Figure 5 shows the relation between the value of the compound R&D option
and the annual arrival intensity for di¤erent levels of market introduction costs
(I1 = 14, 27 and 54). As gure 5 clearly shows, increasing the annual arrival
intensity increases the option value. We assume: V0 = 67; I2 = 19;  = 23%;
T1 = 5; T2 = 1, r = 2:4%, and  ranges from 0 to 100%: Furthermore, when 
approaches 100%, a current value V0 =e67 Million implies a very large project
value when technical failure does not occur. Hence, the option will always
be executed in the (rare) case of no failure. Moreover, due to high technical
risk, formula (7) shows that investment costs are highly discounted, leading to
a relatively high option value of e60 Million. Especially, the cost of market
introduction of e27 Million hardly a¤ects the option value as it is multiplied
with a factor of e 1:0245 = 0:006.
FIGURE 3: Sensitivity analysis between the value
of the compound R&D options and the value of the
project. We assume I1 = 27; I2 = 19;  = 23%;
T1 = 5; T2 = 1, r = 2:4%,  = 7:6% and V0 ranges
from 20 to 100:
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FIGURE 4: Sensitivity analysis between the value
of the compound R&D options and the volatility of
the project value for di¤erent levels of . We assume
V0 = 67; I1 = 27; I2 = 19; T1 = 5; T2 = 1,
r = 2:4%;  = 7:6% (short dashes) and 10% (long
dashes) and nally  ranges from 20% to 100%:
FIGURE 5: Sensitivity analysis between the value
of the compound R&D option and the annual arrival
intensity for di¤erent levels of market introduction
costs. We assume V0 = 67; I1 = 14 (solid curve),
27 (short dashes) and 54 (long dashes), I2 = 19;
 = 23%; T1 = 5; T2 = 1, r = 2:4%, and  ranges
from 0 to 100%:
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5 Concluding remarks
A pharmaceutical R&D investment project can be modeled as a series of sub-
projects, where investment in each step is contingent on the results obtained
from the previous step. Cash ows are not obtained until the last stage, that is,
until the drug is marketed. Because of this property the valuation of pharmaceu-
tical R&D investment projects is one of the most di¢ cult problems. Starting
from the di¢ culty of traditional DCF methods to capture the value of these
projects, the ROV literature provides advanced models, each focusing on di¤er-
ent characteristics. In the present paper we value pharmaceutical R&D invest-
ment projects with the following characteristics: two types of uncertainty, i.e.
technological and economic, and compoundness of R&D projects.
As far as we know, no compound R&D option model in the presence of
technical risk of failure has been studied in the ROV literature before. Including
a Poisson jump process we are able to model the nature of the drug development
process and to assess the option value of pharmaceutical R&D projects in the
presence of technical risk of failure in every R&D stage. Our method shows
that a compound R&D option can be evaluated by conditioning on two possible
scenarios, a failure occurs and does not occur, in each R&D stage. Therefore,
when a technical failure occurs the investment option is abandoned, and thus the
valuation problem boils down to valuing a compound R&D option only under
favorable conditions.
Practical application of this method is emphasized through a case analysis.
We compare an R&D project that has a positive probability of technical fail-
ure and an R&D project that does not to determine the value of a compound
R&D option. Sensitivity analyses are shown as to deepen our understanding
of the determinants of the compound R&D option value. We show that both
uncertainties have a positive impact on the R&D option value. As a second
result, from the sensitivity analysis, we nd that the sensitivity of option value
with respect to changes in the volatility of the underlying value and the cost of
market introduction decreases in the presence of technical uncertainty.
Our method can be easily applied to valuation of sequential (R&D) invest-
ments by di¤erent industries (software development projects in the ICT in-
dustry among others) where there is a positive probability of project failure
in di¤erent stages. Finally, our model can be can be extended to account for
an arbitrary degree of compoundness, i.e. N-nested compound options that
are useful for valuation of early-stage R&D investments and new drug applica-
tions of pharmaceutical companies21 . This extension is included in the appen-
dix.
APPENDIX
A generalization of the model for N-nested compound options.
21See, for example, Cassimon et al., (2004) where R&D projects of pharmaceutical compa-
nies are valued using 6-fold compound options.
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This section shows how the model can be extended to account for an arbi-
trary degree of compoundness and derives an analytical expression for N-nested
compound options.
We consider the valuation problem of a R&D-based pharmaceutical rm
who, at time zero, considers to investing in a drug development project whose
commercial phase cannot be launched before a R&D project consisting of N
stages of investment is completed. Let T1 be the time of the market launch of
the product, when, upon bearing the commercialization cost I1, the rm pock-
ets the project value VT1 . The project payo¤ at time T1 is max fVT1   I1; 0g
and let F1 (V; t) denote the value at time t of this simple investment opportu-
nity. We assume that the commercialization phase is reached upon investing an
amount Ik; at time period Tk; for k = 2; :::; N and with T1  T2  :::  TN .
TN is therefore the time period the project starts and IN is the start up cost,
while Tk and Ik are maturities of intermediate phases which lead up to the com-
mercialization phase and are their respective investment costs. The N staged
investment problem may be viewed as a compound option and its value may be
derived in a recursive way.
Let us now dene a sequence of call options, with value Fk, on the call option
whose value is Fk 1, with exercise price Ik and expiry date Tk, for k = 2; :::; N .
The k fold compound option value can be written in a recursive way and its
nal payo¤ at the options maturity date Tk is given by:
Fk (Fk 1 (V; Tk) ; Tk) = max fFk 1 (V; Tk)  Ik; 0g ; (8)
for k = 2; :::; N and where Fk 1 (V; Tk) stands for the price of the underlying
option at Tk. According to (8), at time Tk, the rm faces the option of in-
vesting an amount Ik, gaining access to stage k   1 of the project whose value
is Fk 1 (V; Tk), or to shut the project down. Our aim is to derive a valuation
formula for the N -fold compound option, that is for FN (V; 0):
Let V k denote the value of V at time Tk such that Fk 1 (V; Tk)   Ik = 0,
for k  2 and V 1 = I1. Then, if the value of V at time Tk, is greater than V k ,
the rm continues to invest in the project, i.e. the compound option will be
exercised, while for values less than V k it will remain unexercised.
Moreover, let us dene ni the number of arrivals in the time interval [Ti+1; Ti] ;
i = 1; 2; :::; N; and let us set TN+1 = 0. Consequently, let mk =
NP
i=k
ni be the to-
tal number of arrivals in the interval [0; Tk], for k = 1; 2; :::; N: The time interval
[0; T1] is divided into subintervals of length k = Tk   Tk+1; for k = 1; 2; :::; N
with N = TN . ni takes the values of zero with probability e  i or one with
probability 1  e  i ; i = 1; 2; :::; N:
Let us dene:
hk =
ln

V0
V k

+
 
r + + 12
2

Tk

p
Tk
; for k = 1; 2; :::; N;
lk = hk   
p
Tk:
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Moreover, let xt be the logarithmic return22 and let the correlation between xTj
and xTi , over the overlapping time interval Tj < Ti, conditional on observing
mj = 0 and mi = 0, respectively, be:
ij =
r
Tj
Ti
; for 1  i < j  N:
For any k; 1  k  N , let (N)k denote a k dimensional symmetric correlation
matrix with typical element ij . Let @k(lk; :::; l1; k) denote the k dimensional
multinormal cumulative distribution function, with upper limits of integration
lk; :::; l1 and correlation matrix k. Finally, assuming that the number of jumps
are independent of each other with a constant arrival intensity , the joint
cumulative probability distribution function of observing n1 = 0, n2 = 0, ...,
nk = 0 in the time intervals 1, 2,..., k; respectively, is H(nk = 0; :::; n1 =
0;) = e (1+2+:::+k); k = 1; 2; :::; N:
The value at time zero of the N -fold compound option, is:
FN (V; 0) = V0@N

hN ; :::; h1; 
(N)
N

+
 
NP
j=1
Ije
 (r+)Tj@N+1 j

lN ; :::; lj ; 
(N)
N+1 j

;
where hj , lj , and ij are as dened previously.
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